Aardvark Therapeutics Shareholders Have Opportunity to Lead Securities Fraud Lawsuit
Investors who experienced losses in Aardvark Therapeutics, Inc. stock have an opportunity to lead a securities fraud class action lawsuit. Law firm Glancy Prongay Wolke & Rotter LLP announced the development.
Shareholders who incurred losses on their investments in Aardvark Therapeutics, Inc. are being given the opportunity to serve as lead plaintiff in a securities fraud class action lawsuit. The law firm Glancy Prongay Wolke & Rotter LLP announced that the lawsuit alleges violations of federal securities laws by the company.
The lawsuit seeks to recover damages for investors who purchased Aardvark Therapeutics securities. According to the announcement, the court will determine who will lead the action. Investors who wish to be considered for the lead plaintiff role must file a motion by a specified deadline.
The firm is encouraging investors who suffered losses to contact them to discuss their rights and options. Further details regarding the filing and eligibility requirements are available through the law firm's public announcements and website.